Celon Pharma S.A. (WSE:CLN)
19.64
-0.14 (-0.71%)
Jul 6, 2026, 5:00 PM CET
Celon Pharma Balance Sheet
Financials in millions PLN. Fiscal year is January - December.
Millions PLN. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 8.35 | - | 26.85 | 32.36 | 82.9 | 147.8 |
Short-Term Investments | 0.75 | - | 48.24 | 82.18 | 81.72 | 79.76 |
Cash & Short-Term Investments | 9.09 | 21.03 | 75.09 | 114.54 | 164.62 | 227.55 |
Cash Growth | -82.69% | -72.00% | -34.45% | -30.42% | -27.65% | 417.42% |
Accounts Receivable | 52.63 | - | 39.26 | 32.79 | 27.11 | 24.67 |
Other Receivables | 14.82 | - | 12.72 | 15.45 | 6.59 | 2.57 |
Receivables | 67.45 | - | 51.99 | 48.24 | 33.7 | 27.25 |
Inventory | 25.17 | - | 30.17 | 26.41 | 38.39 | 23.38 |
Other Current Assets | 3.73 | - | 3.18 | 0.56 | 0.87 | 0.53 |
Total Current Assets | 105.44 | - | 160.43 | 189.75 | 237.58 | 278.7 |
Property, Plant & Equipment | 336.17 | - | 311.66 | 333.8 | 341.59 | 316.57 |
Long-Term Investments | 175.26 | - | 32.56 | 11.26 | 13.25 | 38.12 |
Other Intangible Assets | 21.33 | - | 8.15 | 14.29 | 21.15 | 27.81 |
Long-Term Deferred Tax Assets | 2.22 | - | 21.55 | 19.05 | 28.14 | 31.94 |
Long-Term Deferred Charges | - | - | - | 0.68 | 0.68 | 1.36 |
Other Long-Term Assets | 30.31 | - | 9.46 | 0.47 | 0.38 | 12.64 |
Total Assets | 670.73 | - | 543.8 | 569.31 | 642.76 | 707.14 |
Accounts Payable | 40.99 | - | 15.43 | 10.51 | 17.47 | 11.87 |
Accrued Expenses | 9.88 | - | 8.1 | 7.39 | 6.8 | 3.11 |
Short-Term Debt | 13.25 | - | 1.53 | 12.75 | - | - |
Current Portion of Leases | 7.57 | - | 7.14 | 7.13 | 19.43 | 6.56 |
Current Unearned Revenue | 6.58 | - | 17.92 | 31.09 | 56.42 | 55.83 |
Other Current Liabilities | 9.33 | - | 16.78 | 17.48 | 16.32 | 8.99 |
Total Current Liabilities | 87.6 | - | 66.9 | 86.34 | 116.44 | 86.36 |
Long-Term Leases | 32.32 | - | 8.26 | 5.71 | 7.39 | 8.35 |
Long-Term Unearned Revenue | 20.28 | - | 20.22 | 22.88 | 25.62 | 29.85 |
Long-Term Deferred Tax Liabilities | 0.23 | - | 2.85 | 3.01 | 1.32 | 6.04 |
Other Long-Term Liabilities | 0.98 | - | 0.36 | 5.81 | 12.35 | 22.53 |
Total Liabilities | 141.95 | - | 98.59 | 123.75 | 163.12 | 153.14 |
Common Stock | 5.39 | - | 5.39 | 5.11 | 5.1 | 5.1 |
Additional Paid-In Capital | 516.81 | - | 551.25 | 543.23 | 587.1 | 613.51 |
Retained Earnings | 2.59 | - | -114.96 | -108.64 | -119.79 | -91.67 |
Comprehensive Income & Other | 4.01 | - | 3.53 | 5.85 | 7.23 | 27.07 |
Shareholders' Equity | 528.78 | 389.19 | 445.21 | 445.56 | 479.65 | 554 |
Total Liabilities & Equity | 670.73 | - | 543.8 | 569.31 | 642.76 | 707.14 |
Total Debt | 53.68 | 14.19 | 16.93 | 25.59 | 26.82 | 14.92 |
Net Cash (Debt) | -44.58 | 6.84 | 58.16 | 88.95 | 137.8 | 212.63 |
Net Cash Growth | - | -88.24% | -34.62% | -35.45% | -35.19% | 1049.56% |
Net Cash Per Share | -0.84 | 0.13 | 1.11 | 1.74 | 2.70 | 4.55 |
Filing Date Shares Outstanding | 53.86 | 53.86 | 53.86 | 51.06 | 51.04 | 51 |
Total Common Shares Outstanding | 53.86 | 53.86 | 53.86 | 51.06 | 51.04 | 51 |
Working Capital | 17.85 | - | 93.53 | 103.41 | 121.14 | 192.34 |
Book Value Per Share | 9.82 | 7.23 | 8.27 | 8.73 | 9.40 | 10.86 |
Tangible Book Value | 507.46 | 386.48 | 437.06 | 431.26 | 458.5 | 526.19 |
Tangible Book Value Per Share | 9.42 | 7.18 | 8.12 | 8.45 | 8.98 | 10.32 |
Land | 6.35 | - | 6.35 | 6.35 | 6.35 | 6.35 |
Buildings | 157.97 | - | 157.97 | 146.4 | 146.35 | 146.08 |
Machinery | 377.86 | - | 317.71 | 272.86 | 190.43 | 177.34 |
Construction In Progress | 45.75 | - | 15.75 | 79.95 | 74.3 | 50.63 |